

Thermo Fisher introduces new GMP-manufactured Gibco CTS TrueCut Cas9 Protein

19 April 2022 | News

Gibco CTS TrueCut Cas9 Protein supports the use of genome editing



Thermo Fisher Scientific has introduced the new GMP-manufactured Gibco CTS TrueCut Cas9 Protein. TrueCut Cas9 proteins are manufactured with United States Pharmacopeia standards in mind, including traceability documentation, aseptic manufacturing and safety testing.

Gibco CTS TrueCut Cas9 Protein provides consistent high-editing efficiency in all tested cell lines and greater than 90 per cent efficiency in human primary T-cells, making it a compelling solution for CAR T-cell therapy research using CRISPR-Cas9 genome editing. With the addition of a GMP-manufactured Cas9 protein and the recently launched Gibco CTS Xenon Electroporation System, Thermo Fisher can now support researchers across the autologous T-cell workflow.

The Gibco CTS TrueCut Cas9 Protein is part of the Thermo Fisher's Cell Therapy Systems (CTS) product line, a comprehensive portfolio of GMP-manufactured products supported by traceability documentation. This product line is designed to work synergistically across the entire workflow, from cell isolation/activation to cell engineering and expansion, to address cell therapy developers' manufacturing needs.